Better futures for young lives with epilepsy and associated conditions
A- A A+
Donate Now Helpline: 01342 831342 (Mon-Fri, 9am-3pm)
Switchboard: 01342 832243 (Mon-Fri, 8.30am-5pm)
Menu

A feasibility study of the use of Betashot

Betashot - a feasibility study of the use of Betashot, a medium chain triglyceride-based (MCT) formula for special medical purposes in children and adults with epilepsy

Aim

The feasibility study is to evaluate the use of Betashot, an MCT based food for special medical purposes. This study aims to determine whether a product, primarily consisting of Decanoic Acid (C10) is well tolerated in a population of individuals with epilepsy.

What this means

This is a tolerability study related to  the ketogenic diet works but research suggests that medium chain fatty acids (MCTs) may be key in the efficacy of the diet. We hope this product, if tolerable by patients, will ease the demanding ketogenic diet administration.

Update

This tolerability study recruited adults and children with compelx epilepsy, completed at the end of July 2017. The first patient was recruited in July 2016 and we have recruited 60 patients into the trial.

Investigators

Matthew Walker, Helen Cross, Sanjay Sisodiya, Simon Heales, Rumana Jalil, Natasha Schoeler.

Cyber EssentialsFundraising RegulatorYoung Epilepsy is the operating name of The National Centre for Young People with Epilepsy (NCYPE).
Registered Charity number 311877 (England and Wales)

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site
EU Cookie Directive plugin by www.channeldigital.co.uk